Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Corcept Therapeutics (CORT) , which belongs to the Zacks Medical - Drugs industry.When looking at the last two reports, this drug developer has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 46.97%, on average, in the last two quarters.For the last reported quarter, Corcept came out with earnings of $0.28 per sh ...

MENLO PARK, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the appointment of Roberto Vieira as President, Oncology. He will report to Joseph K. Belanoff, MD, Corcept's Chief Executive Officer, and join the company's Executive Team. Mr. Vie ...

Corcept Therapeutics Incorporated (NASDAQ:CORT) Q3 2023 Earnings Call Transcript November 1, 2023 5:00 PM ET Company Participants Atabak Mokari - Chief Financial Officer Charlie Robb - Chief Business Officer Joseph Belanoff - Chief Executive Officer, President and Director Sean Maduck - President, Corcept Endocrinology William Guyer - Chief Development Officer Conference Call Participants Matthew Kaplan - Ladenburg Thalmann David Amsellem - Piper Sandler Roanna Ruiz - Leerink Joon Lee - Truist Operator Good ...

Cushing's Syndrome Treatments - Korlym is marketed in the United States for treating Cushing's syndrome, with a focus on patient access through specialty pharmacy and distributor support, alongside patient assistance programs[96] - Relacorilant, a selective cortisol modulator, is in Phase 3 trials (GRACE and GRADIENT) for Cushing's syndrome, with 152 patients enrolled in GRACE and 130 planned for GRADIENT[97][98][99] - The GRADIENT trial aims to study relacorilant's effects on glucose metabolism and hypertension in patients with benign adrenal tumors, with half receiving the drug and half receiving placebo for 22 weeks[99] - Relacorilant has been designated as an orphan drug by the FDA and EC, offering tax credits, reduced fees, and exclusive marketing rights for 7 years in the U.S. and 10 years in the EU[114] - The CATALYST Phase 4 study aims to evaluate the prevalence of Cushing's syndrome in up to 1,000 patients with difficult-to-control diabetes, with potential randomization to Korlym or placebo for 24 weeks[111] Financial Performance and Expenses - Stock-based compensation expense for 2023 totaled $12.9 million for the three months and $36.0 million for the nine months, compared to $10.6 million and $32.1 million in 2022, respectively[103] - Income tax expense for the three and nine months ended September 30, 2023, was $5.0 million and $13.0 million, respectively, compared to a benefit of $1.6 million and expense of $7.1 million in 2022[106] - Research and development expenses for the three and nine months ended September 30, 2023, were $4.0 million and $11.2 million, respectively, compared to $3.1 million and $9.7 million in 2022[103] Stock Options and Compensation - As of September 30, 2023, the company had 23.3 million stock options, 0.1 million RSUs, and 0.7 million RSAs outstanding, compared to 23.5 million, 0.2 million, and 0.2 million in 2022[105] Tax and R&D Regulations - The Tax Cuts and Jobs Act of 2017 requires U.S. and foreign R&D expenditures to be amortized over five and fifteen years, respectively, with no modifications as of September 30, 2023[108]

Corcept Therapeutics Incorporated (NASDAQ:CORT) Q2 2023 Earnings Conference Call August 2, 2023 5:00 PM ET Company Participants Joseph Belanoff - Chief Executive Officer, President and Director Atabak Mokari - Chief Financial Officer Charlie Robb - Chief Business Officer William Guyer - Chief Development Officer Sean Maduck - President, Corcept Endocrinology Conference Call Participants Matthew Kaplan - Ladenburg Thalmann Edward Nash - Canaccord Genuity David Amsellem - Piper Sandler Roanna Ruiz - Leerink J ...

For the transition period from to Commission File Number: 000-50679 _______________________________________________________ CORCEPT THERAPEUTICS INCORPORATED (Exact Name of Corporation as Specified in Its Charter) _______________________________________________________ Delaware 77-0487658 (State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.) 149 Commonwealth Drive Menlo Park, CA 94025 (Address of principal executive offices, including zip code) __________________ ...

Call Start: 17:00 January 1, 0000 5:41 PM ET Corcept Therapeutics Incorporated (NASDAQ:CORT) Q1 2023 Earnings Conference Call May 3, 2023 17:00 ET Company Participants Atabak Mokari - Chief Financial Officer Charlie Robb - Chief Business Officer Joseph Belanoff - Chief Executive Officer Bill Guyer - Chief Development Officer Conference Call Participants Matt Kaplan - Ladenburg Thalmann David Amsellem - Piper Sandler Edward Nash - Canaccord Genuity Roanna Ruiz - SVB Securities Greg Fraser - Truist Operator G ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________ FORM 10-Q _______________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50679 CORCEPT THERAPEUTICS ...

Corcept Therapeutics Incorporated (NASDAQ:CORT) Q4 2022 Earnings Conference Call February 28, 2023 5:00 PM ET Company Participants Atabak Mokari - Chief Financial Officer Charlie Robb - Chief Business Officer Joseph Belanoff - Chief Executive Officer Bill Guyer - Chief Development Officer Sean Maduck - President of Endocrinology Division Conference Call Participants Raymond Wu - Ladenburg Thalmann Dennis Ding - Jefferies Greg Fraser - Truist Arthur He - H.C. Wainwright Operator Greetings, and welcome to the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50679 CORCEPT THERAPEUTICS INCORPORATED (Exact Name of Corporation as Specified in Its Charter) Delaware 77-0487658 (State or other jurisdictio ...